The global radiopharmaceuticals market could reach $6.63 billion by 2017, according to a report from market research firm Global Industry Analysts (GIA).
The study cites an aging global population and increasing cardiovascular, oncological, and neurological disorders as two reasons for the anticipated growth. In addition, burgeoning product development in new clinical applications, a promising product pipeline, escalating demand for PET, and increasing research efforts also will propel the global market.
The projected growth would represent a rebound for the global radiopharmaceuticals market, which experienced a deceleration in 2008 and 2009 due to financial constraints, inflationary pressures, loss of insurance coverage, and a reduction in the number of insured people, according to GIA.
The market bounced back last year with the resurgence of hospital spending on SPECT/CT scanners and other diagnostic and medical equipment, the report noted.
